-
If you can discover why an employee performed a job incorrectly, which caused a near-miss accident that could have been fatal to other workers, wouldn't this information be priceless to you?
-
Geisinger Health Plan's patient-centered medical home pilot project, which placed case managers in primary care practices, reduced hospital admissions for heart failure, pneumonia, chronic obstructive pulmonary disease, and the frail elderly within six months, and ultimately demonstrated a 20% reduction in hospital readmissions.
-
Sonia Hoffman, RN, BSN, a Geisinger Health Plan case manager who works at a primary care clinic, tells the following story of how her interventions kept a woman with severe chronic obstructive disease out of the hospital and avoided unnecessary utilization of health care resources:
-
As the Patient Protection and Affordable Care Act makes sweeping changes in the health care environment, case managers have the opportunity to be the critical link between the patients and providers.
-
Case Management Week, Oct. 10-16, offers a great opportunity for case managers to educate members of the public and people within their own organizations about case management, says Teri Treiger, RN-C, MA, CCM, CCP, new president of the Case Management Society of America (CMSA).
-
A one-size-fits-all education about heart disease is not a good strategy, according to Holly Andersen, MD, director of education and outreach at the Ronald O. Perelman Heart Center at New York-Presbyterian Hospital Weill Cornell Medical Center in New York City.
-
-
Although some aspects of vaginal birth after cesarean delivery (VBAC) have been covered in previous OB/GYN Clinical Alert issues, I cannot pass up an opportunity to comment on two papers appearing in the June issue of Obstetrics & Gynecology.
-
Carcinosarcoma of the uterus is a rare condition accounting for less that 4% of all uterine neoplasms. Previous work has identified that the most active single agents are platinum, ifosfamide, paclitaxel, and doxorubicin.
-
Without fanfare, the FDA approved oral tranexamic acid tablets (Lysteda), the first non-hormonal product cleared to treat heavy menstrual bleeding in the United States.
